By Clinical Leader, Mary Varghese Presti, Sébastien Bohn – IBM Watson Health
If you’re a clinical trial executive involved in any aspect of trial design, it’s likely in the past few years you’ve faced a new dilemma — and not the one associated with how to run trials in a COVID-19 world. You’re collecting more patient data than ever before, which is good, but your ability to fully leverage the insights derived from that data is being hampered. The culprit? Those very same data collection systems you put in place years ago.
Whether it be your CTMS, CDMS, RBM, ePRO, or any of the other various applications that constitute your clinical trial ecosystem, there’s a good chance that some data silos exist. Some people may say that lack of integration amongst certain programs is just the cost of doing business, or they may incur actual costs for customized programming to connect disparate systems. But these days, isn’t the goal to trim clinical trial expenses while also increasing the speed at which trials are designed and conducted?